Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare time to progression and overall survival after
treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the
first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of
the head and neck.